Lymphatic vascular aging and age-related bone loss: current status and future perspectives
Authors:
Open Access
- 1 September 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1900206
Abstract
Age-related bone loss is a major contributor to osteoporosis and fragility fractures in older adults. Skeletal aging is accompanied by reduced bone mineral density, impaired bone microarchitecture, chronic low-grade inflammation, and immune dysregulation. Lymphatic vascular aging refers to age-related structural and functional decline of lymphatic vessels. This decline impairs immune surveillance and inflammatory mediator clearance, thereby disrupting tissue homeostasis. Age-related lymphatic dysfunction impairs drainage and inflammatory clearance. This allows inflammatory mediators, including IL-6 and TNF-α, to persist in bone-associated tissues, thereby promoting osteoclastogenesis and resorption-dominant remodeling. Age-related lymphatic dysfunction also affects VEGF-C/VEGFR-3 signaling, chemokine-mediated immune trafficking, and marrow niche support. These changes link drainage failure to osteoimmune imbalance and delayed bone repair. Current evidence supports a link between lymphatic vascular dysfunction and skeletal degeneration. Most evidence comes from animal models, bone injury studies, or diseases with secondary lymphatic defects, whereas direct clinical evidence in human age-related osteoporosis remains limited. This review summarizes current evidence linking lymphatic dysfunction to skeletal degeneration, examines the context-dependent roles of lymphatic remodeling in skeletal homeostasis, and discusses emerging therapeutic strategies targeting the lymphatic-bone axis. Future studies should define clinically relevant lymphatic alterations and determine whether restoring lymphatic homeostasis can mitigate age-related bone loss.Keywords
This publication has 125 references indexed in Scilit:
- Bone Aging, Cellular Senescence, and OsteoporosisJBMR Plus, 2021
- Effect of VEGFC on lymph flow and inflammation‐induced alveolar bone lossThe Journal of Pathology, 2020
- Impairment of the Glymphatic Pathway and Putative Meningeal Lymphatic Vessels in the Aging HumanAnnals of Neurology, 2020
- Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham–Stout diseasePediatric Blood & Cancer, 2019
- “Inflamm‐aging” influences immune cell survival factors in human bone marrowEuropean Journal of Immunology, 2017
- Lymphatic Endothelial Cells Produce M-CSF, Causing Massive Bone Loss in MiceJournal of Bone and Mineral Research, 2016
- Plasma cell numbers decrease in bone marrow of old patientsEuropean Journal of Immunology, 2014
- Bone Cell Senescence: Mechanisms and PerspectivesJournal of Bone and Mineral Research, 2014
- Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritisArthritis & Rheumatism, 2009
- Lymphatic versus blood vascular endothelial growth factors and receptors in humansMicroscopy Research and Technique, 2001